Replimune Group (REPL) Stock Price, News & Analysis

-0.09 (-1.40%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
631,809 shs
Average Volume
1.33 million shs
Market Capitalization
$388.60 million
P/E Ratio
Dividend Yield
Price Target

Replimune Group MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
495.1% Upside
$37.67 Price Target
Short Interest
17.40% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($3.28) to ($2.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.47 out of 5 stars

Medical Sector

93rd out of 909 stocks

Biological Products, Except Diagnostic Industry

10th out of 156 stocks

REPL stock logo

About Replimune Group Stock (NASDAQ:REPL)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Stock Price History

REPL Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Replimune appoints new CEO ahead of drug application
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
REPL Apr 2024 10.000 call
REPL Mar 2024 10.000 put
Replimune Group Inc (REPL)
REPL Feb 2024 30.000 put
See More Headlines
Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$9.80 per share


Free Float
Market Cap
$385.53 million
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Philip Astley-Sparke F.S.A. (Age 53)
    CEO & Director
    Comp: $1.07M
  • Dr. Sushil Patel Ph.D. (Age 53)
    Chief Strategy Officer
    Comp: $665.05k
  • Dr. Robert Coffin Ph.D. (Age 59)
    Founder, President, Chief Research & Development Officer and Director
    Comp: $785.89k
  • Ms. Emily Luisa Hill (Age 44)
    Chief Financial Officer
  • Dr. Colin A. Love Ph.D. (Age 66)
    Chief Operating Officer
    Comp: $419.37k
  • Mr. Andrew Schwendenman (Age 48)
    Chief Accounting Officer & Treasurer
  • Dr. Pamela Esposito Ph.D. (Age 50)
    Chief Business Officer
    Comp: $464.63k
  • Ms. Tanya N. Lewis M.S. (Age 53)
    Chief Development Operations Officer
    Comp: $4.7k
  • Mr. Christopher Sarchi (Age 56)
    Chief Commercial Officer
  • Dr. Konstantinos Xynos M.B.A. (Age 58)
    M.D., Ph.D., Chief Medical Officer

REPL Stock Analysis - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings
or view top-rated stocks.

What is Replimune Group's stock price target for 2024?

3 analysts have issued 12-month target prices for Replimune Group's stock. Their REPL share price targets range from $13.00 to $52.00. On average, they predict the company's share price to reach $37.67 in the next twelve months. This suggests a possible upside of 495.1% from the stock's current price.
View analysts price targets for REPL
or view top-rated stocks among Wall Street analysts.

How have REPL shares performed in 2024?

Replimune Group's stock was trading at $8.43 on January 1st, 2024. Since then, REPL shares have decreased by 24.9% and is now trading at $6.33.
View the best growth stocks for 2024 here

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024.
View our REPL earnings forecast

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) released its earnings results on Thursday, February, 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.12.

What ETF holds Replimune Group's stock?

Horizon Kinetics Medical ETF holds 14,396 shares of REPL stock, representing 0.60% of its portfolio.

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?

Replimune Group (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.11%), Denali Advisors LLC (0.06%) and Diversified Trust Co (0.02%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis.
View institutional ownership trends

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:REPL) was last updated on 4/24/2024 by Staff

From Our Partners